

# Winter 2007 Impact

www.dana-farber.org and www.jimmyfund.org

Thanking those who make a difference.



## Institute Trustee Stephen Kay endows professorship with \$3.3 million campaign gift

For a quarter of a century, Institute Trustee Stephen Kay has helped to govern Dana-Farber, playing a critical part in its landmark achievements and helping to establish its stellar reputation. Now, as the Institute embarks on its comprehensive capital campaign, *Mission Possible*:

*The Dana-Farber Campaign to Conquer Cancer*, he has further strengthened that commitment by making a gift of \$3.3 million to create and endow the Stephen B. Kay Family Professorship in Medicine at Harvard Medical School and DFCI.

"I think it is incumbent upon people who have been around a long time and have been deeply involved in the Institute to set an example," said Kay. "If we don't make a gift early, why should those on the periphery?"

Kay, a retired senior director of Goldman, Sachs & Co., has been an Institute trustee since 1981, was treasurer of the board of trustees for eight years, now chairs the Investment Committee, and serves on four additional trustee committees, including the Executive and Capital Campaign Committees. In addition to his longstanding support for several Institute initiatives, he has hosted a chamber music concert in his home for the past six years as a fundraiser for the Dana-Farber Marathon Challenge.

Kay sees the campaign as essential to Dana-Farber's future. "Without it, we will not be competitive with other frontline cancer centers around the country," he said. "Dana-Farber



Institute Trustee Stephen Kay (right) celebrates the appointment of longtime friend Robert Mayer, MD, director of DFCI's Center for Gastrointestinal Oncology, as the first Stephen B. Kay Family Professor in Medicine at Harvard Medical School and DFCI.

continued on page 6

## C.J.L. Charitable Foundation advances translational breast cancer research

Dana-Farber's longstanding belief in the power of collaboration between basic and clinical scientists, specifically translational research, has led to remarkable advances in understanding and effectively treating cancer. The need for such a united effort is vital to accelerate breast cancer research as studies now show that many forms of the disease can benefit from a unique treatment strategy. To fuel further progress, the C.J.L. Charitable Foundation recently made a \$1.35 million gift to establish the Lurie Breast Cancer Tissue and Translation Initiative within DFCI's Women's Cancers Program.

This venture will help the Institute build an infrastructure to support translational breast cancer research and provide momentum for DFCI's comprehensive capital campaign. A team of researchers and scientists has been recruited to collect, bank, and study tissue and blood samples from patients in order to better understand, heal, and, ultimately, prevent the disease more effectively.

Thanks to this initiative, Dana-Farber's team will use these samples to understand the impact of treatment in various patient groups. Since breast cancer is not a single disease, but a family of diseases, each woman may have a unique reaction to the treatment she receives, depending on her specific type of tumor. By combining biological information from patient tissue and blood samples with clinical information, such as treatment response, physicians will ultimately be able to personalize care.



Thanks to the support of the C.J.L. Charitable Foundation, Eric Winer, MD, and his colleagues are expanding their translational breast cancer research program by developing treatment strategies tailored to each patient's disease.

Winer, MD, director of DFCI's Breast Oncology Center. "By linking clinical information with cancer tissue and blood from the same patient, we can gain a finer understanding of why certain treatments work and others fail. In the years ahead, treatments will differ based on the subtype of breast cancer and on the individual patient. The ultimate goal is individualized care, and this gift takes us another step in that direction." ■

"The foundation will facilitate a remarkable amount of research with this generous gift," said J. Dirk Iglehart, MD, director of the Women's Cancers Program at DFCI and chief of Surgical Oncology at Brigham and Women's Hospital. "We can now study samples from patients with breast cancer, including participants in Dana-Farber-sponsored clinical trials, as well as women at risk for the disease because of a family history. The study of these patient-derived tissues is critical in order to really understand how breast cancer starts, progresses, and responds to treatment."

In addition, this funding will allow DFCI researchers to collect samples from patients with metastatic breast cancer, an incurable disease that claims the lives of at least 40,000 women each year in the United States alone. Analyzing tissue samples from these patients will enable scientists to better understand the biology of metastatic disease and focus on developing targeted treatments, as well as determining how to prevent the disease from spreading.

"This initiative will allow us to extend the scope of our translational research program in breast cancer," said Eric



3  
Tremendous Trek



5  
Fashionable Friends



6  
Spirited Sprinters



8  
Patriotic Patrons



9  
Angelic Alliance

## Dear Friends,

Dana-Farber scientists and physicians are finding that new technologies are indispensable in the search for genetic and molecular causes of cancer. Several Institute researchers have shown that creating new technologies is often a necessary first step toward discovery, especially in the new and quickly evolving disciplines of cancer genetics and genomics.

Novel science demands novel tools, and among the many gifts we celebrate in this *Impact* are several that specifically fund cutting-edge technology.

We say thank you to longstanding donors Donna and Michael Egan for their recent \$1 million gift to advance breast cancer research through a new technology. Their gift supports the development of a new way to sequence DNA, designed both to speed the process and reduce its cost. While the gift underwrites an effort to find the genetic aberrations that lead to breast cancer in women under 40, this groundbreaking science and techniques could eventually be used to advance all cancer research.

In addition, Ralph Bates, a new friend of the Institute, recognized the crucial link between 21st century research and the need for new technology with his \$1 million gift, half of which created the Ralph E. Bates Cancer Research and Technology Fund. Bates was inspired to make his gift after seeing and hearing Dana-Farber patients and staff on the fifth Annual WEEI/NESN Jimmy Fund Radio-Telethon last August. We are delighted by his spontaneous generosity.

We are grateful, also, to the Marion Huber Trust for its \$1 million gift, most of which will fund the Center for Applied Cancer Science, a multidisciplinary research center aimed at the new science of bioinformatics, with its powerful focus on putting the data gleaned from genetic analysis to work in a clinical setting.

While technology is vital to discovery, talent to drive this technology is equally critical, and, in this *Impact*, we thank longtime Institute Trustee Stephen Kay for his extraordinary \$3.3 million gift to the capital campaign, endowing the Stephen B. Kay Family Professorship in Medicine at Harvard Medical School and DFCI. We are thrilled by his incredible support of the Institute's faculty and of this historic campaign.

The gifts from these friends and all of Dana-Farber's supporters are crucial in enabling discovery and putting science to work to control cancer. With your generosity, we are paving the way for new therapies—and a better future for cancer patients. Thank you all.

Susan S. Paresky  
Senior Vice President for Development



## Mission Possible: The Dana-Farber Campaign to Conquer Cancer

### Campaign funding to fuel Institute's top priorities

Publicly launched Jan. 31, Dana-Farber's \$1 billion capital campaign is the catalyst that will enable the Institute to change the cancer landscape and, ultimately, conquer the disease. To make its mission possible, Dana-Farber seeks investments in four critical areas:

#### Research and Care: \$450 million

The campaign will enable the Institute to build upon its hallmark: a unique 50–50 balance between cancer research and patient care. Like no other, Dana-Farber has invested equally in laboratory-based discoveries and patient- and family-centered care, pursuing each with equal determination and vigor. The result has been a potent convergence of the two, enabling the creation of a robust pipeline for drug discovery and the rapid translation of laboratory breakthroughs into effective new treatments that extend and save lives.

#### Technology: \$100 million

Achieving the next round of cancer breakthroughs demands powerful new tools that enable investigators to penetrate the complexities of cancer cells. A number of new and emerging technologies hold tremendous potential to accelerate the pace and progress of cancer research. The campaign will fuel Dana-Farber's investment in five core technology platforms—chemical biology, computational biology, genomics, imaging, and proteomics—that are essential to the rapid development of targeted new treatments.

#### The Center for Cancer Care: \$150 million

The most visible funding priority of the campaign is the construction of a new, state-of-the-art clinical facility. To accommodate its dramatic rise in patient volumes, Dana-Farber will break ground this spring on its 275,000-square-foot, 13-story Center for Cancer Care. The facility will house 100 exam rooms, 150 infusion chairs, and the Clinical Research Center, which will accommodate an increasing number of patients participating in clinical trials.

#### The Jimmy Fund and Unrestricted Funds: \$300 million

The Jimmy Fund and unrestricted support provide flexible funding that benefits the entire Institute and supports its most pressing needs, now and in the future. Gifts without restriction are critical to the Institute's successes and are crucial to the campaign because they provide funds to use where and when they are needed most. As our patient care, research, education, and outreach initiatives continue to grow, so too does our need for this steady, adaptable funding. ■

MISSION POSSIBLE

The Dana-Farber Campaign to Conquer Cancer

To learn how you can be a part of the campaign to conquer cancer, contact Julia Parrillo, campaign director, at 617-632-6573 or via e-mail at [julia\\_parrillo@dfci.harvard.edu](mailto:julia_parrillo@dfci.harvard.edu).

MISSION POSSIBLE

The Dana-Farber Campaign to Conquer Cancer

Help Dana-Farber make its mission possible.

## Impact

Winter 2007 • Volume 10 • Issue 1

This issue covers gifts received and finalized through the fall and winter of 2006.

*Impact*, a newsletter of Dana-Farber Cancer Institute and the Jimmy Fund, is published by the Department of Communications in collaboration with the Division of Development for friends and supporters of Dana-Farber and the Jimmy Fund.

**President, Dana-Farber Cancer Institute**  
Edward J. Benz Jr., MD

**Chief of Staff**  
Stephen E. Sallan, MD

**Chief Medical Officer**  
Lawrence Shulman, MD

**Chief Scientific Officer**  
Barrett Rollins, MD, PhD

**Chair of Medical Oncology**  
James Griffin, MD

**Chair of Pediatric Oncology**  
Stuart H. Orkin, MD

**Senior Vice President for Development**  
Susan S. Paresky

**Chairman of the Jimmy Fund**  
Michael J. Andrews

**Senior Vice President for Communications**  
Steven R. Singer

**Impact Editors**  
Brian Geer, Dawn Stapleton

**Contributors**  
Sara Allen, Jared Berezin, Alan Caplan, Karen Cummings, Erin Danby, David Ferreira, Daniel Morris, Katie Quackenbush, Susan Rice, Patrick Rooney, Beth Rossi, Lora Sharpe, Susan Turner, Coral Vogel, Lesley Yoder

**Art Director**  
John DiGianni

**Designer**  
Irina Zlobina

**Production Coordinators**  
Tiffany Amoakohene, Kathleen Raven

**Photographers**  
Jeff Cleary, Lisa Cohen, John Deputy, Joe Durkin, Steve Gilbert, Visko Hatfield, Shawn Henry, Bill Horsman, Justin Knight, Sam Ogden, Richard Schultz, Aaron Washington

Requests for copies of *Impact* may be sent to:

**DFCI Development Office**  
10 Brookline Place West, 6th Floor  
Brookline, MA 02445-7226  
617-632-3019

or download an issue at [www.dana-farber.org/impact](http://www.dana-farber.org/impact)

Dedicated to Discovery...Committed to Care

Dana-Farber Cancer Institute provides expert, compassionate care to children and adults and is home to groundbreaking cancer discoveries. Since its founding in 1948, Dana-Farber's Jimmy Fund has raised millions of dollars through thousands of community efforts to advance this lifesaving mission.

## Maiches continue to build on two decades of support

For 20 years, Institute Trustee Peter Maich and his wife, Mary Ellen, have been ardent supporters of Dana-Farber, contributing their financial support as well as through volunteer work. Mary Ellen served as president of the Jimmy Fund Council of Greater Boston, volunteered in the infusion rooms with patients, and served as a co-chair of the From Fenway to the Runway luncheon and fashion show. With their recent unrestricted gift of \$250,000, the Maiches reaffirmed their commitment to DFCI by providing unrestricted support

for its new Center for Cancer Care, a funding priority of *Mission Possible: The Dana Farber Campaign to Conquer Cancer*. “Right now, I know there is a big push to near the finish line in this fight against cancer,” said Peter Maich. “Unrestricted funds are more difficult to raise, and we wanted to be sure Dr. Benz [DFCI President Edward J. Benz Jr., MD] and his staff have the flexibility to maximize their effectiveness in finding cures.”

The Maiches have supported research into both women’s cancers and prostate cancer in the past, and, by choosing to fund the Institute’s Center for Cancer Care on Brookline Avenue with this unrestricted support, their gift will go to fuel the most critical and immediate needs of the Institute as it expands its space.

“The new building is more than just a physical place,” said Benz. “It will be designed to optimize the connections between our scientists and clinicians as they make the discoveries that will become tomorrow’s cures. That would not be possible without generous people like the Maiches.” ■



Mary Ellen and Peter Maich are continuing their longtime support of Dana-Farber by ensuring that the Institute, and those who depend on it, have a bright future.



Ralph Bates (center), shown here with (left to right) friend Jimmy Pratt, Dana-Farber Associate Director of Major Gifts Karen Sveda, and Jimmy Fund Chairman Mike Andrews, recently gave \$1 million to support DFCI’s technology platform and its planned Center for Cancer Care.

## Ralph Bates tunes in and steps up to combat cancer

Last August, after listening to the radio broadcast of the fifth annual WEEI/NESN Jimmy Fund Radio-Telethon, retired businessman Ralph Bates was inspired to join the Institute’s fight against cancer.

“They worked so hard, trying to make that money,” said Bates about the patients, families, caregivers, and celebrities who shared their experiences during the 2006 Radio-Telethon. “I thought I could probably help them reach their goal quicker.” Moved by the touching stories of the broadcast, Bates resolved to help by making a \$1 million gift to Dana-Farber. Half established the Ralph E. Bates Cancer Research and Technology Fund to support DFCI’s technology platform, and the other \$500,000 will support the construction of the new Center for Cancer Care building.

“After hearing so many good things on the radio and visiting the Jimmy Fund Clinic myself, I knew that I couldn’t go wrong by doing something like this, seeing how the money is being used and observing the great work that’s being done there,” Bates recalled.

### Foundation for the future

Scientists and researchers need access to the latest cutting-edge technology in order to accelerate the transformation of new discoveries into effective therapies and cures. The Institute’s technology platform helps procure sophisticated technologies for five major disciplines: genomics, pro-

teomics, chemical biology, imaging, and computational biology.

“As scientists, we now understand that the basis of cancer lies in genetic abnormalities,” explained DFCI’s Chief Scientific Officer Barrett Rollins, MD, PhD, who will direct the Bates Fund. “In order to translate that knowledge into new treatments and potential cures, a huge investment in technology has to take place. Generous gifts like Mr. Bates’ allow this to happen.”

Not only will Bates’ gift make a lasting impact on the Institute’s technology platform, it will also support *Mission Possible: The Dana-Farber Campaign to Conquer Cancer*. Because a cornerstone of the Institute’s comprehensive capital campaign is the construction of a new patient care and clinical research facility at 450 Brookline Avenue, \$500,000 of Bates’ gift will aid in its completion. The 13-story, 275,000-square-foot structure will house 100 exam rooms and 150 infusion chairs, supporting the increased translation of scientific discoveries into improved patient therapies, and serving as the Institute’s new welcoming front entrance. Scheduled to open in 2011, it will be Dana-Farber’s first new building for clinical care in more than 30 years.

“I applaud Ralph for his generosity,” said Jimmy Fund Chairman Mike Andrews. “He is not only a special person, but a member of our Jimmy Fund family as well. His heartfelt gift will bring us closer to the possibility of eliminating this disease in our lifetime.” ■

Boston Red Sox player Kevin Youkilis invites you to give \$5 to the Jimmy Fund and, in return, wear your Sox gear to work on Opening Day, April 10. Join or start a Rally team, and the highest fundraising team will win a visit from “Youk” himself.



To learn more, visit [www.rallyagaincancer.org](http://www.rallyagaincancer.org) or contact Charles Savicki at 617-632-5420.



## PMC riders go the distance with record \$26 million gift

The 2006 Pan-Massachusetts Challenge (PMC) bike-a-thon raised a record \$26 million for the Jimmy Fund, surpassing last year’s total by \$3 million and bringing the event’s 27-year tally to more than \$171 million. On Nov. 2, PMC Founder and Executive Director and Institute Trustee Billy Starr (center) presented the check, representing the largest charity gift ever raised by an athletic fundraising event, to Dana-Farber President Edward J. Benz Jr., MD (right), and fellow Institute Trustee

Larry Lucchino, president and CEO of the Boston Red Sox, a presenting sponsor of the PMC.

On Aug. 5 and 6, 4,300 cyclists tackled one of eight routes, ranging from 70–192 miles. Benz, who was dubbed a “rookie PMC-er” by Starr, joined the participants who came from 36 states and six countries in the two-day ride. The PMC contributes more than 99 cents of every rider-raised dollar to cancer research and care at Dana-Farber.

## The Ellison Medical Foundation searches for links between cancer and aging

The Ellison Medical Foundation is committed to supporting researchers focused on unlocking the basic biology behind aging, with the hope that this knowledge will ultimately lead to more effective treatments for age-related diseases. Recently, the foundation awarded a \$600,000 Senior Scholar Award to DFCI's Bruce Spiegelman, MD, who is attempting to apply this type of research to the development of cancer and neurodegeneration therapies.

"The world's population is aging rapidly, and how and why we age are the great mysteries of science," said Richard Sprott, PhD, executive director of The Ellison Medical Foundation. "Basic research has the greatest potential to provide long-term solutions to age-related diseases, such as cancer, and other age-related problems."

The foundation's award allows Spiegelman to pursue studying the role in the aging process of a toxic chemical byproduct called reactive oxygen species (ROS), which is produced when the body converts food molecules into energy. Typically, the body releases enzymes that seek and destroy any excess ROS. However, when this process falters, cells deteriorate. This is a symptom of aging and other degenerative diseases. Encouragingly, Spiegelman has discovered a set of proteins called PGC-1 coactivators

that suppress the formation and accumulation of ROS.

"The Senior Scholar Award will enable me to examine how these pro-

teins can control ROS levels," said Spiegelman. "I will test the effect of elevated levels of the proteins in animal models and explore possible therapies that can be used to regulate these levels in cells."

The Ellison Medical Foundation recognizes that supporting this area of research can lead to potentially powerful breakthroughs.

"Support for basic research is the hardest funding to find," said Sprott. "Most support is aimed at specific diseases because those problems are very visible, while basic biological processes are not. Understanding these processes is the best hope we have of finding ways to prevent, cure, or put into remission age-related diseases and disabilities." ■

**"Basic research has the greatest potential to provide long-term solutions to age-related diseases, such as cancer, and other age-related problems."**

— Richard Sprott, PhD



## Nuclea Biomarkers targets Loda and Chin for latest gifts

Fresh off last spring's establishment of a research fellowship in the laboratory of Dana-Farber's Massimo Loda, MD, director of DFCI's Center for Molecular Oncologic Pathology, Institute supporter Nuclea Biomarkers, LLC, is displaying its generosity again. The biotechnology services company's gift of \$145,000—\$120,000 to Loda and \$25,000 to his DFCI colleague Lynda Chin, MD—is furthering research into targeted therapeutics through the use of cutting-edge, multi-spectral imaging technology, which captures cancer tissue images at different wavelengths of light to simultaneously quantify multiple biomarkers.

"The research of Drs. Loda and Chin is groundbreaking," said Nuclea Biomarkers President and CEO Patrick Muraca. "Our hope is that they can discover new gene signatures from which targeted therapies can be developed. Targeted therapeutics address the specific needs of the patient."

Tools available to predict biological behavior and response to therapy are limited at present, but Loda remains optimistic. "Recent data, such as Dr. Chin's array-CGH work detecting microscopic differences between genomes, has shed light on potential biomarkers and has highlighted targets we hope will allow us to tailor therapy to the unique molecular composition of each tumor," said Loda.

Muraca's vision of combating disease echoed Loda's statement. "The future of medicine is in personalized therapeutics," opined Muraca. "Nuclea is working with Dana-Farber to achieve this by putting theories into practice, where results become so important." ■



Nuclea Biomarkers President and CEO Patrick Muraca remains committed to supporting DFCI's search for targeted therapeutics.



SAY "I DO"



... and honor your guests with Dana-Farber Favors.

Choose among our elegant selection of favors, or personalize your own to inform guests that you have made a gift in their honor to support the lifesaving mission of Dana-Farber and the Jimmy Fund.

View and order your favors online at [www.jimmyfund.org/favors](http://www.jimmyfund.org/favors) or call Caitlin Kraus at 617-632-6099.

## Borhek's gift of gratitude gives hope to brain cancer patients

For most of their life together, Anne Borhek knew her husband, William, was strong. She will always remember "his boundless energy, his amazing positive outlook on life, and his excellent health." Then, tragedy struck when William was diagnosed with a glioblastoma, a life-threatening brain tumor. The couple immediately sought treatment and turned to neurologist Jan Drappatz, MD, for his expertise in helping patients battle the disease. Unfortunately, William's cancer proved too aggressive, and he succumbed to the disease in 2004. However, Borhek never forgot Drappatz' commitment to helping her husband.

"Dr. Drappatz was so compassionate and patient in walking us through every step of the treatment," recalled Anne Borhek. "His level of care and concern was just so incredible."

By establishing the \$100,000 William F. Borhek Fund for Brain Tumor Research, directed toward Drappatz's work in Neurology at Dana-Farber, she has found a way to recognize his efforts while honoring her late husband's memory. With this fund, Drappatz and DFCI's Patrick Wen, MD, will lead the search for new discoveries and develop new therapies to combat various forms of brain tumors.

"My hope for this gift is that it will prevent people from having to go through what my husband did," said Anne Borhek. "If it helps just one person, I will be so grateful. I feel very fortunate that I am able to give this gift to help others, and I know that my husband would be very proud." ■



Though he lost his battle with glioblastoma, William Borhek's legacy lives on through a gift made by his wife, Anne, to fuel brain tumor research at DFCI.

## Cutlers' campaign gift fuels lung cancer research and campus expansion

Over the last 20 years, Stephen and Alice Cutler and their children have proven themselves to be among Dana-Farber's biggest fans, contributing both their time and their financial support to the Institute's lifesaving mission. Alice Cutler is an active member of the Friends of Dana-Farber, an all-volunteer organization at the Institute, and previously served as both its president and co-president, and the couple have also been active with the Institute's community of Palm Beach supporters in Florida.

The Cutlers recently wrote a new chapter in their philanthropic history with a \$1 million gift toward *Mission Possible: The Dana-Farber Campaign to Conquer Cancer*. Half of their gift will help fund Dana-Farber's new state-of-the-art Center for Cancer Care, while the other \$500,000 will create the Alice and Stephen D. Cutler Investigator Fund in Thoracic Oncology.

"Alice and I believe that it is absolutely crucial



With their recent \$1 million gift to Dana-Farber, Stephen and Alice Cutler are fueling growth of DFCI's campus and its Thoracic Oncology Program.

for us to support Dana-Farber at this important time," said Stephen Cutler. "We hope that, with this gift, we will be able to see the payoff of all of the Institute's vital cancer-fighting efforts in the very near future, while at the same time furthering the excellent patient and family care services offered by the Institute."

The gift will allow the Institute to carry out its plan to expand its current campus with the construction of a 13-story building at 450 Brookline Avenue, which will provide much-needed space for both patient care and clinical research. Ground-breaking for this new structure, a main funding priority of the campaign, is slated for this spring.

### A crusade for cures

For the Cutlers, funding the fight against thoracic cancers is a personal priority. Having lost her own father to lung cancer, Alice Cutler knows firsthand the devastating effects the disease can have on patients and their loved ones. With this gift, the Cutlers hope to help scientists push the boundaries of understanding and treat these hard-to-control cancers.

"There is just not enough support for this terrible disease," explained Alice. "There are misconceptions and horrible stigmas still attached to lung cancer. We hope that this fund will go a long way toward generating gains in both research and public awareness for the disease."

Fueled by this gift, the researchers in DFCI's Carole M. and Phillip L. Lowe Center for Thoracic Oncology now have the wherewithal to make a significant impact in both treatment and promoting preventive and monitoring measures.

"It is donors like Alice and Stephen Cutler who are making all the difference for Dana-Farber," said Institute President Edward J. Benz Jr., MD. "With their generosity in funding both our novel research and the new building, they are helping us make huge leaps in our mission to conquer cancer." ■



## Saks and Friends of Dana-Farber team up to unlock the "Key To The Cure"

Saks Fifth Avenue's "Key To The Cure" national shopping weekend, which took place from Oct. 12-15, 2006, has historically given \$50,000 annually to the Women's Cancers Program at Dana-Farber. This year, the Friends of Dana-Farber Cancer Institute enjoyed success with its annual fundraiser thanks to a stylish new twist.

On Oct. 18, following the four-day shopping event, the Friends treated enthusiastic shoppers to a special celebration and unveiling of the newly renovated first floor of Saks Fifth Avenue's Prudential Center store in Boston.

Led by chairs (left to right) Christina Glen, Micki Hirsch, Dana Gerson, and Lisa London, guests dedicated 100 percent of their ticket price to one of four charities. Dana-Farber received the most, raising \$43,000 for cancer research and patient care.

1 in 31,000 golfers will make a hole-in-one.

1 in 3 people will be diagnosed with cancer.



## Change the odds.

To learn more about hosting, playing, or sponsoring a Jimmy Fund Golf tournament, call Amy McCallum at 866-521-GOLF or visit us at [www.jimmyfund.org/golf](http://www.jimmyfund.org/golf).

## Taco Bell coins new program to help fight cancer



By serving as a Patient Partner, Hunter Donigan, 4, helped Taco Bell launch its new fundraising program, Coins for Cancer.



Last fall, Taco Bell, Inc., reinvigorated its longstanding partnership with the Jimmy Fund by launching Coins for Cancer, a new fundraising program that raised nearly \$105,000 for cancer care and research at Dana-Farber.

From Oct. 18 to Nov. 8, customers at 105 Taco Bell restaurants in the six New England states and New York were asked to drop their change into the Jimmy Fund canisters prominently displayed at each cash register and drive-through window. Placards next to each canister featured the smiling face of 4-year-old Hunter Donigan, a current Jimmy Fund Clinic patient partner, which served to remind patrons whom their generosity would be helping.

"Taco Bell is proud to support the Jimmy Fund and Dana-Farber in their efforts to conquer cancer," said David Lockwood, executive vice president of Lockwood/McKinnon Company in Norwood, Mass., the Taco Bell franchisee that spearheaded the promotion. "We have been energized in our launch of Coins for Cancer and are grateful to our fellow franchisees, Taco Bell's participating restaurants, our employees, and, especially, our customers for their support of this new initiative."

Jimmy Fund Chairman Mike Andrews added, "We are very grateful that Taco Bell continues to give such enthusiastic support to the fight against cancer. Their new promotion is part of the time-honored tradition of the Jimmy Fund, which collected nickels, dimes, and quarters to construct the very first building at Dana-Farber in 1952. With the Institute growing so dramatically, Taco Bell's support is more important than ever." ■

## Doris Duke Charitable Foundation selects two Dana-Farber researchers for competitive awards

The 2006 competition for Doris Duke Clinical Scientist Development Awards was fierce—of the unprecedented 178 applicants, only 23 were selected to receive the three-year, \$405,000 grants. Included in this elite group were two of Dana-Farber's most promising doctors: Matthew Freedman, MD, and Ross Levine, MD.

"We are thrilled to see this surge in interest among young doctors embarking on clinical research career paths," said


foundation President Joan E. Spero. "The foundation doubled the number of awards it was planning to offer this year, recognizing that the current budgetary constraints will make grants from the National Institutes of Health increasingly competitive."

The award was designed to provide start-up funding for junior physician-scientists making the transition to independent research careers, helping them to establish their own labs and teams while protecting time for designated clinical research. Since 1998, the foundation has given 105 of these awards, totaling approximately \$47 million. "Without funding to start their labs, these talented young physician-scientists could easily direct their careers away from research," said Spero, "which would be a great loss to the field."

With his award, Freedman will continue his efforts to answer a major question: Why do certain men die from prostate cancer, while others live with the disease?

"It is likely [physicians] are over-treating a large percentage of men destined to have a slow growing disease, and in the process, subjecting them to side effects," said Freedman. "Our goal is to provide a molecular decision-making tool to help clinicians differentiate between an aggressive and indolent course of disease. This, in turn, would allow doctors to more effectively counsel patients regarding their prognosis."

"Thrilled" was Levine's description of his reaction after learning that he had received the support to continue investigating the genetics behind disorders that cause an overproduction of blood cells in the bone marrow. With the award, Levine plans to uncover mutations that cause these diseases by using existing genetic screens as well as creating new ones, then developing treatments that specifically target these mutations. ■



Support from the Doris Duke Charitable Foundation is providing DFCI physician-scientists Matthew Freedman, MD (left), and Ross Levine, MD, the necessary seed funding to establish their own independent laboratories.

## Runners work to keep cancer research on course

The Dana-Farber Runners set the pace in the race for cancer cures at the sixth annual B.A.A. Half Marathon® on Oct. 8. As DFCI team members trained for this year's 13.1-mile race through Boston's Back Bay, they joined together off the track to raise \$244,300 collectively to support the Institute's cancer-fighting mission.

In its fourth year as the event's participating sponsor, Dana-Farber and the Jimmy Fund showed there was strength in numbers with its team of 250 runners. Gregory Burkus (pictured here), who took the lead in the fundraising race, not only raised thousands but also crossed the finish line dedicated to accelerating research and patient care at Dana-Farber.



## Kay, continued from page 1

can't earn these funds like a company can. They have to come from philanthropy."

A Harvard alumnus and former overseer of the university, Kay is delighted that his family's name will be linked to a professorship at the medical school. And he is thrilled that his longtime friend Robert Mayer, MD, director of DFCI's Center for Gastrointestinal Oncology, has been chosen as the first Kay Professor.

"He is a very close friend, and he was wonderful to my late wife," said Kay. Nan Bennett Kay passed away in 2001 from breast cancer. Her primary physician was Eric Winer, MD, director of DFCI's Breast Oncology Center, and Kay recalls not only Winer's compassion, but also the warmth Mayer showed Nan during her illness. "He's an old-fashioned doctor in the way he cares about patients," said Kay.

The award of an endowed chair is another milestone in Mayer's long career dedicated to patients, research, and educating young oncologists. He is vice chair for academic affairs in the Department of Medical Oncology at Dana-Farber and has directed the Institute's fellowship training program since 1975. He heads the Institute's third-largest patient care center, and, as a leader in his field, helps guide national gastrointestinal cancer research policies. In addition, he has published extensively on the disease's possible causes, treatments, and prevention efforts.

"It is my great privilege to serve as the first Stephen B. Kay Family Professor in Medicine at Harvard Medical School," said Mayer. "I have long admired Steve and am so very honored by the generosity that he and his family have shown in creating this endowed position." ■

**RUNNING THE RACE AGAINST CANCER**

Participate in road races, triathlons, and marathons around the globe in support of cancer research and treatment at Dana-Farber Cancer Institute.

[www.jimmyfund.org/running](http://www.jimmyfund.org/running) E-mail: [dfrunners@dfci.harvard.edu](mailto:dfrunners@dfci.harvard.edu)

## Brauer family's gift promotes advancements in melanoma research

In honor of her late husband, David Brauer, Pegge Brauer is continuing the family's commitment to fighting melanoma with a generous gift of \$100,000 to establish the Brauer Family Fund for Melanoma Research at Dana Farber. The fund supports further investigations into the disease with the fervent hope for its eventual eradication.

The fund is managed under the direction of F. Stephen Hodi, MD, the clinical director of DFCI's Melanoma Program and one of the country's leading researchers into immunotherapy and treatments for metastatic melanoma.

The Brauer family maintains a very personal connection with Hodi, who was also David's physician for five years and remained tirelessly committed to the family. "We have a lot of faith in Dr. Hodi, and I know that Dave would be very pleased that we are supporting him in this way," Brauer explained.


The family's gift is an important contribution to the advancement of melanoma research and to Hodi's own investigations into more effective treatment options that are less toxic to the system.

"The generosity of the Brauer Family Fund offers hope for the development of novel therapeutics for melanoma that would otherwise not be possible," Hodi said. "It is through their kindness that new concepts for intervening in this disease can move forward to implementation in patients." ■



Support from the Brauer Family Fund for Melanoma Research will allow DFCI's F. Stephen Hodi, MD, and his colleagues to continue their important search for more effective treatments in combating the disease.

## Egans advance genetic research with technology



A \$1 million gift from Michael and Donna Egan will advance research into a new DNA screening technology led by Alexander Miron, PhD (above), and J. Dirk Iglehart, MD.

Inspired by the promise of research at Dana-Farber that has the potential to both speed and reduce the cost of DNA sequencing, Michael and Donna Egan have made a \$1 million gift to underwrite this groundbreaking effort. Led by J. Dirk Iglehart, MD, director of the Women's Cancers Program (WCP) at DFCI and chief of Surgical Oncology at Brigham and Women's Hospital, and Alexander Miron, PhD, of Cancer Biology, the project focuses on those genes implicated in the development of basal-like breast cancer, a particularly aggressive form of the disease.

The Egans have supported the Institute's breast cancer research for many years, and, with other gifts, established the Egan Women's Cancers Program Research Fund to help researchers define subsets of breast cancer and demonstrate, with a technology called gene expression profiling, that breast cancer is not a single disease and, therefore, requires individualized therapies. The identification of the basal subtype has led to the current work.

### New process to be faster, cheaper

The Egans' latest gift, made as part of the Institute's comprehensive capital campaign, will take those findings several steps further. Miron has developed novel methods to find changes in genes' DNA. With the Egans' gift, he and his team will be able to obtain advanced equipment, and further automate and miniaturize this innovative process, now known as Exon Grouping Analysis (EGAN). According to Miron, the EGAN process "will be 100 times faster and 100 times cheaper" than standard gene sequencing.

"We're very interested in basic research, and we were looking for a new opportunity to fund," said Donna Egan. "Dr. Iglehart introduced us to Dr. Miron, and we found his research to be really exciting, creative, and goal-driven. We believe that with an influx of capital, Dr. Miron and his colleagues could get something really big going that would impact patients all across the board."

Rather than sequencing a patient's entire genetic code, which scientists did for the Human Genome Project, Miron, with the help of EGAN, quickly scans the genes to find differences among them. When genes are mutated, they change shape, making them stand out in the crowd of genes in the modified DNA sequencer and pinpointing genetic behavior that may lead to cancer. EGAN also accurately analyzes DNA samples in a miniaturized fashion, compared to standard DNA sequencing; this saves time and cuts costs. The Egans hope that this research opens a new way of investigating cancer.

**"Quite simply, the Egans' gift is indispensable. They have allowed us to take this research to the next level. We couldn't have taken this step without them."**

— Alexander Miron, PhD

and will drive years of productive research. All of us at Dana-Farber, in the Women's Cancers Program and the patients we serve, owe Donna and Michael Egan a giant thank you."

Adds Miron, "Quite simply, the Egans' gift is indispensable. They have allowed us to take this research to the next level. We couldn't have taken this step without them." ■

"The Egan gift enables us to take a great leap forward," said Iglehart. "This technology will lead to information about the genetics of cancer that was impossible to imagine before,



### Platelet donors recognized for giving the gift of life

On Oct. 29, the Kraft Family Blood Donor Center at DFCI hosted a recognition brunch at Gillette Stadium in Foxboro, Mass., to thank those individuals who have donated blood platelets over the past two years. The event's speakers, including Shannon McBride, a DFCI patient, and platelet donor Gary Jerneagan, emphasized the importance of donating these clotting agents, which control bleeding and are essential to patients undergoing cancer treatments.

The center was established in 1983 through a generous gift from Institute Trustee Robert Kraft, owner of the New

England Patriots football team, and his family. During the brunch, more than 300 guests enjoyed a buffet breakfast and speaking program, which was made even more special by an impromptu visit from New England Patriots players Daniel Graham and Stephen Neal.

Left to right: Daniel Kraft; Kenneth Anderson, MD, director of DFCI's Jerome Lipper Multiple Myeloma Center and the Kraft Family Professor of Medicine at Harvard Medical School; Robert Kraft; and Institute President Edward J. Benz Jr., MD, stand united in the fight against cancer.

## Procter & Gamble joins Gillette in its commitment to fight women's cancers

Since its establishment of the Gillette Center for Women's Cancers at Dana-Farber in 1997, The Gillette Company has partnered with DFCI's Women's Cancers Program (WCP) to fuel efforts in treating and combating breast and gynecologic cancers. With its most recent gift of \$175,000, Gillette and its parent company, Procter & Gamble, are now supporting the WCP in its ongoing efforts to treat patients, both medically and emotionally.

"The Women's Cancers Program offers a unique and holistic approach to cancer treatment that is focused on all the needs of both an individual and her family," said Brian Hodgett, spokesperson for Procter & Gamble/Gillette. "The Gillette Center's Program is focused not just on treatment of the disease, but on providing the best possible 'total care.'"



*World-Class Brands, Products, People*

With this gift, the WCP will be able to continue in its mission to support women throughout all of cancer's stages, including the transition from patient to survivor. A portion of this gift will also help to fuel accessibility to women's cancers education and screenings in underserved areas of Boston, particularly via visits to these communities by DFCI's Boston Mammography Van.

"The support from Procter & Gamble/Gillette is critical to our ability to serve our community and its neighborhoods, places of business, and all women who need cancer screening and advanced cancer care," said J. Dirk Iglehart, MD, director of the Women's Cancers Program and chief of Surgical Oncology at Brigham and Women's Hospital. ■

## AVEO Pharmaceuticals fuels multiple myeloma research

**H**oping to push the boundaries of multiple myeloma research, AVEO Pharmaceuticals Inc. has created a new \$150,000 fellowship in the Jerome Lipper Multiple Myeloma Center at Dana-Farber. The 2006 AVEO Fellow, scientist Steffen Klippel, PhD, will utilize these funds to propel his studies into understanding the basic molecular mechanisms surrounding myeloma, an incurable form of bone marrow cancer. He will work under the direction of Kenneth Anderson, MD, director of the Lipper Center and the Kraft Family Professor of Medicine at Harvard Medical School, whose previous groundbreaking success in translating myeloma research into cancer therapies spurred the gift.

“Like Drs. Anderson and Klippel, we believe that application of sound scientific principles to modeling cancer in the laboratory can provide means for better understanding of drug responses across diverse patient populations, leading to faster and more effective drug development,” said Steven Clark, PhD, chief scientific officer at AVEO.



Klippel's investigations will also include examining new treatments, both protein-based drugs and small-molecule inhibitors, that target the growth of cancer cells while leaving the healthy cells alone. These inhibitors show promise as potential new therapies that are easier for patients to tolerate.

“The ultimate goal of our research is to cure myeloma or at least to improve the quality of our patients' lives,” said Klippel. “It is exciting to see pharmaceutical companies and scientists join together to find more effective cancer therapies. With AVEO's generous support, we are confident our studies will lead to better treatment options for our patients.” ■

## Determined survivor continues fight against gastrointestinal cancers

**I**n the fall of 2005, Bob Bennett was diagnosed with colon cancer that had metastasized to his liver. Upon learning of his diagnosis, he was struck by two emotions: confusion and determination. “There was confusion because everything I would experience over the next year was new and uncharted territory for me,” recalled Bennett, senior vice president with Berkshire Hathaway Credit Corporation.

But it was that second emotion, determination, which led this husband and father of two to overcome the odds and emerge as a cancer survivor and, most recently, a DFCI contributor. Bennett is supporting his primary oncologist, Charles Fuchs, MD, MPH, director of Dana-Farber/Harvard Cancer Center's Gastrointestinal Malignancies Program, with a gift of \$100,000.

Initially given a grim prognosis, Bennett attributes a great deal of his remarkable recovery to the combination of chemotherapy and novel biological agents administered by Fuchs. Following this treatment, a biopsy performed on his excised liver cancer led to an astonishing outcome: The innovative combination therapy had not only shrunk the tumors, but had killed them, as well.

Being one of only a handful of patients with such a successful response, Bennett, along with his wife, Julie, was eager to support Fuchs and his research to discern why some patients respond favorably to new therapeutic protocols and others do not.

“Bob has incredible strength and recognizes the unique opportunities currently in GI cancers,” said Fuchs. “This funding will allow us to look at genetic and genomic markers in tumors to arrive at new targeted therapies.” ■



Bob Bennett, seen here with his son Jake, continues to support the battle against gastrointestinal cancers.

## Cutlers fight a “silent” disease with Ovarian Cancer Research Fund

**B**ecause it often goes undiagnosed until it has metastasized, ovarian cancer is known as the “silent” disease. And with fewer than 20 percent of advanced ovarian cancer patients achieving long-term cures, Randi and Joel Cutler recognized the urgency of the battle against the disease. Their recent gift of \$100,000 to establish the Randi and Joel Cutler Ovarian Cancer Research Fund at Dana-Farber is a bold display of their commitment to conquering this form of cancer.



Longtime Dana-Farber supporters Randi and Joel Cutler have made a generous gift with the goal of focusing the research lens on ovarian cancer.

The Cutlers are longtime supporters of Dana-Farber, and Randi Cutler is also an active member of the Women's Cancers Program Executive Council, a group dedicated to advancing women's cancer research through advocacy and financial support.

“We know early detection is critical in treating any disease, and it's terrifying that no simple, effective, or reliable test currently exists for detecting ovarian cancer,” said Randi Cutler.

A recent study led by Ronny Drapkin, MD, PhD, an investigator in the Center for Molecular Oncologic Pathology at Dana-Farber, has identified ovarian cancer biomarkers that may help detect the disease in its earliest stages. This research has reached a critical juncture, and the Cutlers' gift will enable Drapkin and his team to expand their efforts, with the hope of generating a test for early detection, uncovering risk factors, and developing new treatments.

“Joel and I are big believers in the power of research,” Randi Cutler added. “Hopefully our gift will provide information and options to women sooner rather than later.” ■



## Patriots tickets are a gift that keeps on giving

Dana-Farber received national attention in August 2005 when it was presented with the naming rights to the New England Patriots' training facility at Gillette Stadium in Foxboro, Mass., thanks to a generous gift from Institute Trustee Jack Blais and his wife, Shelley. In addition, the Blaises also contributed a block of tickets to each Patriots home football game for the following 10 seasons, as well as 50 passes to pre-game tailgate parties held at the Dana-Farber Field House, where guests enjoy complimentary food, beverages, and the chance to meet some of the Patriots cheerleaders.

DFCI utilized this act of generosity to raise funds for its lifesaving mission by auctioning and raffling the ticket packages at over 50 events throughout 2006. In the end, this effort yielded more than \$140,000.

Pictured above: New England Patriots cheerleaders visit with DFCI supporters Joshua Drew and his father, Kyler, in the Dana-Farber Field House prior to the Sept. 10 game against the Buffalo Bills.

## IWMF award propels research into rare blood cancer

Though many have never heard of Waldenström's macroglobulinemia, there are several thousand people currently battling this rare, incurable cancer that creates a thickening of the blood. In an effort to fight this disease, the International Waldenström's Macroglobulinemia Foundation (IWMF) recently awarded \$1.2 million to Steven Treon, MD, PhD, as he leads Dana-Farber's Bing Center for Waldenström's Research, which aims to further understand and, one day, conquer this disease.

"As patients with Waldenström's macroglobulinemia, we remember quite clearly what it feels like to be given the news that we have an incurable cancer with an almost unpronounceable name," said Judith May, president of the IWMF. "We've



watched Dr. Treon build something that is just amazing. He has formed a team that is very committed, and we believe that their research will result in something very concrete."

### The search for a cure

The IWMF began in 1994 when Arnold Smokler, a retired pharmacist, was diagnosed with Waldenström's. At the time, there was little information on the disease and no organized support group, so Smokler formed his own group that eventually grew into a renowned non-profit organization providing information, resources, a communications network, encouragement, and emotional support for those living with this disease.

Treon was among the first researchers funded by the IWMF in 1999. Three

years later, he approached the foundation with a plan to create a "national center of excellence for WM," which he envisioned would combine both laboratory and clinical research.

"I think the dream that had been put forward is now being realized," said Treon. "We've been able to attract top scientists from all over the world to help us advance the basic science behind this disease."

Treon believes this year will mark the most significant development yet for his team, as they have identified an antibody designed to attack what he refers to as "the heart and soul of WM."

"Dr. Treon seems very optimistic that breakthroughs are right around the corner," added May. "And we all share in his enthusiasm." ■



At a recent symposium, DFCI's Steven Treon, MD, PhD (third from left) presented his team's research to several members of the International Waldenström's Macroglobulinemia Foundation, including (left to right) Guy Sherwood, Tom Myers, President Judith May, James Berg, and Jim Bunton.

## "Angels" have a ball raising funds for multiple myeloma research

On Sept. 23, the Corman family invited 900 guests to kick up their heels for Dana-Farber, raising \$100,000 through the Angel Ball in Nicholasville, Ky. Rick Corman has a history with DFCI both as a patient battling multiple myeloma and a steadfast donor. Joining Corman's philanthropic efforts, his sister Sandy Adams organized this festive fundraiser held in Corman's airplane hangar to benefit the Richard Corman Fund in Multiple Myeloma at Dana-Farber.

Adams said that it was her love for her brother that inspired the Angel Ball, which raised a total of \$265,000, with the funds split between Dana-Farber and the local Jessamine County Hospice in Kentucky. "It's personal," said Adams. "It's just the two of us—Ricky and me. I have a personal desire to find a cure and keep my brother alive as long as possible."

Guests dined, danced, and bid on fabulous auction prizes, including a Ford 500 Series sedan and backstage concert passes donated by the evening's special guest, Eddie Montgomery, of the country music group Montgomery Gentry.



DFCI patient and supporter Rick Corman (second from left) is pleasantly surprised by his team of DFCI physicians (left to right) Kenneth Anderson, MD, Paul Richardson, MD, and Teru Hideshima, MD, PhD, who traveled from Boston to Kentucky to attend the Angel Ball, organized by Corman's sister, Sandy Adams.


For Corman, the most memorable moment was seeing his Dana-Farber physicians, Paul Richardson, MD; Kenneth Anderson, MD, director of DFCI's Jerome Lipper Multiple Myeloma Center and the Kraft Family Professor of Medicine at Harvard Medical School; and Teru Hideshima, MD, PhD, who made a surprise visit from Boston to attend the event.

"Rick is a very dear friend and an extraordinary patient," said Richardson. "He and Sandy have a clear desire to help others and a deep sense of commitment to tackle this disease in every way possible." ■

## DFCI supporters convene for annual Visiting Committees meeting

This year's meeting of the Dana-Farber Visiting Committees was held at the newly opened Westin Boston Waterfront on Nov. 15 and 16. The membership of the various committees—Gastrointestinal Cancer Center, Lank Center for Genitourinary Oncology, Hematologic Oncology, the Jimmy Fund, and Women's Cancers Program—comprises business and community leaders who share in the Institute's mission to provide the best and most compassionate care to its patients while leading the way in innovative research.

Though the Women's Cancers Program committee held a separate session on Nov. 7, the remaining four groups were in attendance as the annual summit kicked off on the evening of Nov. 15 with a dinner and keynote address by Thomas R. Cech, PhD, president of the Howard Hughes Medical Institute and a Nobel Prize winner (pictured above, with DFCI President Edward J. Benz Jr., MD). Cech spoke about the importance of supporting innovative translational medicine and the physician-scientists who bridge the divide between the laboratory and clinic. The following day, the committees gathered to discuss the work of their respective groups and the new opportunities and challenges for the year to come.



## Celgene and DFCI strengthen collaboration efforts to cure myeloma

Eight years ago, Kenneth Anderson, MD, director of Dana-Farber's Jerome Lipper Multiple Myeloma Center and the Kraft Family Professor of Medicine at Harvard Medical School, began conducting research with a then-new drug developed by biopharmaceutical company Celgene Corporation to treat multiple myeloma. Today, that drug, Revlimid®, has gained FDA approval as an oral treatment for multiple myeloma patients who have been previously treated with other therapies. Hoping to conduct further research into more effective therapies for this cancer of the blood, Celgene recently honored DFCI with a new \$1 million gift supporting Anderson's cutting-edge work.

"Together with Dana-Farber, Celgene believes multiple myeloma can be cured through the power of collaboration," said Sol Barer, PhD, president and chief operating officer of Celgene.

This generous gift represents the best spirit of partnership between Dana-Farber and companies who share the Institute's vision to develop cancer cures. Celgene, an integrated global pharmaceutical company headquartered in Summit, N.J., maintains a primary focus on the discovery, development, and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through immunomodulatory agents and gene and protein regulation. Dana-Farber is hoping to utilize Celgene's resources to help conquer this deadly disease.

### United against a common enemy

The nation's second most common blood cancer, multiple myeloma currently affects more than 15,000 new individuals in the United States every year. Despite recent advances in therapies, it remains an incurable disease, as many patients relapse or develop a resistance to their treatments. Thanks to Celgene's support, Anderson and his colleagues are able to further investigate new therapies for these patients.

"It has been an extraordinary pleasure for us to work together with Celgene on both preclinical and clinical studies culminating in the FDA approval of Revlimid to treat patients with myeloma," said Anderson. "It truly is a model of academic and industry collaboration that fast-forwards progress toward a cure. This new gift will assure that, together, we go on to rapidly identify, validate, and clinically test the next generation of myeloma therapies to further improve the outlook for patients worldwide." ■



Institute President Edward J. Benz Jr., MD (second from left), joins Celgene's Jerome Zeldis, MD, PhD, (left) and Sol Barer, PhD, (second from right) in celebrating the company's new gift to support multiple myeloma research by Dana-Farber's Kenneth Anderson, MD.

## PRESIDENT'S CIRCLE

DISCOVERY • COMPASSION • IMPACT

### Make an executive decision to fight cancer.

The Dana-Farber President's Circle is a giving society that recognizes supporters who have made annual gifts of \$1,500. To learn more about making a yearly commitment at this level to join this group, please visit [www.dana-farber.org/circle](http://www.dana-farber.org/circle) or call Kim Goff at 617-632-3949.

## STEP UP TO THE PLATE AND FIGHT CANCER!™

Sport the official Jimmy Fund/Boston Red Sox Massachusetts license plate on your car.

Go to [www.jimmyfund.org/plate](http://www.jimmyfund.org/plate) to order your plate.



## BJ's partnership again supports advances in women's cancers research

BJ's Wholesale Club Inc. marked the fifth anniversary of its Vendor Partner Program by rallying its family of suppliers to collectively contribute more than \$500,000 for research in the Women's Cancers Program (WCP) at Dana-Farber. Altogether, this winning team effort has raised more than \$2.5 million for the WCP, making it one of the Institute's most successful corporate giving initiatives.

Launched by BJ's Chairman Herb Zarkin, the program ran from Sept. 16 to Nov. 15. Team captains in each of the company's departments promoted Dana-Farber's groundbreaking work and urged the company's vendors to contribute to the cause.



BJ's Vendor Partner Program has contributed more than \$500,000 in 2006 to further research by DFCI's Women's Cancers Program, headed by J. Dirk Iglehart, MD.

### Business becomes personal

While Zarkin and his family have supported the Institute for many years, BJ's Vendor Partner Program took up the cause of women's cancers after Institute Trustee Amy Zarkin Reiner, Zarkin's daughter, was diagnosed with breast cancer and was successfully treated at DFCI. Today, as a survivor, she is an active Dana-Farber trustee.

"BJ's is proud to serve the community in many ways, and our partnership with Dana-Farber is particularly important," Zarkin said. "Our unique Vendor Partner Program gives critical resources to promising research in women's cancers and, ultimately, is paving the way for a better future for patients everywhere. I'm delighted to thank both our wonderful vendors and our dedicated employees for taking such an enthusiastic part in this program."

BJ's commitment has been "a lifesaver" for WCP research initiatives, according to J. Dirk Iglehart, MD, director of the WCP and chief of Surgical Oncology at Brigham and Women's Hospital. "At a time when federal dollars for medical research are shrinking, we turn to our business partners and private donors to propel advancement in biology and medicine," said Iglehart. "BJ's and its affiliated vendors have once again stepped up and provided us with the funding to sustain our momentum. This extraordinary gift is critical for our research into women's cancers."

### A second gift supports women's cancers

In addition to its Vendor Partner Program, BJ's also shared the proceeds from sales of pink-ribboned apparel in its 170 stores with Dana-Farber. BJ's Charitable Foundation, which oversees the sales, saw this second annual merchandise initiative raise a total of \$375,000 for DFCI and six other East Coast breast cancer research and treatment centers. ■



## Jimmy Fund Council of Western Massachusetts celebrates 25 years

The Jimmy Fund Council of Western Massachusetts held its annual meeting and celebrated its 25th anniversary on Nov. 13. Comprised of more than 50 committed volunteers, the council has raised well over \$6 million since 1981, including \$879,876 in 2006 to help promote Dana-Farber's efforts to conquer cancer.

Over the past quarter century, the council has hosted many successful annual fundraising events, including: the Jimmy Fund Golf Tournament/ Jeffrey Vinick Memorial, the Dawn to Dusk Golf Tournament, the Katelynn's Ride bike-a-thon, and the Great Chefs culinary showcase. It has also fielded the very triumphant "Amy's Admirers" Boston Marathon® Jimmy Fund Walk team. Each of these events is volunteer-run and supported by the Jimmy Fund's Western New England Regional Office, located in West Springfield, Mass.

Above: Jimmy Fund Council of Western Massachusetts President Andrew Cohen and Janet Caparoso, director of the Western New England Regional Office, cut the cake in celebration of 25 successful years of fundraising for DFCI and the Jimmy Fund.

## Campbells leave a legacy of hope

**D**orothy and Charles Campbell spent their life together by the sea on Cape Cod, in a house situated just one mile from the water. According to their niece, Priscilla Isner, the couple loved the ocean.

"My uncle loved to fish," said Isner, "and one of the great joys of my aunt's life was walking Nauset Beach every afternoon."

That happiness was shattered when Dorothy was diagnosed with skin cancer. The disease metastasized, and Dorothy subsequently died of lung cancer in 2004. However, the Campbells ensured that their ordeal with cancer would have a positive impact on the lives of others: They made a bequest of more than \$300,000 to Dana-Farber.

"They hoped that some day there would be a cure," Isner said, "and that nobody would have to suffer like my aunt did."

Charles Campbell, a Cape Cod native, spent many years in the U.S. Navy and Naval Reserves before he and Dorothy married and moved to Orleans, Mass.

After Dorothy died, Charles spent as much time on the water as he was able until his own death in 2005. It was then that Dana-Farber Cancer Institute learned of the couple's planned gift.

"The Campbells' generosity leaves a meaningful legacy," said DFCI President Edward J. Benz Jr., MD. "Theirs is a gift of hope, inspiring those who continue to battle this disease." ■



*Cape Cod natives Charles and Dorothy Campbell left a meaningful legacy with a generous bequest to Dana-Farber Cancer Institute in support of cancer research.*

## Marion Huber Trust fuels CACS's research and treatments

**D**ana-Farber's Center for Applied Cancer Science (CACS) is one of eight integrative research centers established at DFCI to bring together scientists and researchers from various disciplines to work collaboratively and help accelerate the transformation of discovery into effective patient therapies. A critical source of the centers' funding comes from private support, such as bequests, which are directed to the Institute through an individual's will or trust.

Thanks to a gift of more than \$700,000 from the Marion Huber Trust, the CACS is set to advance its fight against the most lethal forms of cancer. The funds will establish the Huber-Francis Memorial Endowment in support of research at the center. One of the first initiatives bolstered by the gift will be the drug discovery pipeline for pancreatic cancer.

The fourth leading cause of cancer death, pancreatic cancer presents few symptoms before reaching an advanced stage and carries a high mortality rate.

"Each year, there are approximately 30,000 people diagnosed with pancreatic cancer, and all but several hundred will succumb to the disease following a relentless and merciless course of pain and wasting," said CACS Director Ronald DePinho, MD, who will oversee the direction of the Huber-Francis fund. "We have taken on the challenge to change those numbers, and this gift will help us in our efforts to combat this disease."

The timing of this gift could not be better. Previous donor support has provided DePinho and his colleagues with the means and technology to develop the first mouse model that mirrors the progress of pancreatic cancer in humans. "With this knowledge, we are now able to identify targets, or biomarkers, that will aid in the discovery of potential, effective therapies," explains DePinho. "Support from the Huber-Francis Memorial Endowment will allow us to expand our basic knowledge of this disease and accelerate the application of such insights into effective CACS drug development initiatives." ■



*Ronald DePinho, MD, director of DFCI's Center for Applied Cancer Science, is expanding research into pancreatic cancer thanks to a gift from the Marion Huber Trust.*

## Step by step, FFANY and QVC fight breast cancer at annual gala

**Q**VC Inc. and the Fashion Footwear Association of New York (FFANY) put their best feet forward to raise more than \$3 million for breast cancer research and education at the 13th annual FFANY Shoes on Sale<sup>SM</sup> event held Oct. 18 in New York City. The televised gala featured an auction of more than 60,000 pairs of designer shoes, with proceeds benefiting six leading breast cancer programs across the nation, including the Women's Cancers Program (WCP) at Dana-Farber.

The WCP has been a beneficiary of the event for more than a decade and, to date, has received more than \$3 million for its breast oncology programs. A delegation from DFCI, led by Eric Winer, MD, director of the Breast

Oncology Center, was on hand to celebrate this year's success.

"Dana-Farber is proud to partner with FFANY and QVC in the fight against breast cancer," said Winer.

"We are extremely grateful for their steadfast commitment, which

allows us to conduct critical research that will ultimately help to eliminate suffering and mortality from this very common disease."

Hosted by actress Carmen Electra, the event included a surprise appearance by "The Sopranos" star Jamie-Lynn Sigler, whom FFANY named its "Celebrity Fashion Muse." Among others, this year's festivities also honored Jimmy Choo as Fashion Footwear Company of the Year, Christian Louboutin as Designer of the Year, and Zappos.com as Innovative Retailer of the Year. Singer/songwriter Mya provided the entertainment for the evening. ■

**Dana-Farber Cancer Institute**  
Division of Development & The Jimmy Fund  
10 Brookline Place West, 6th Floor  
Brookline, MA 02445-7226

Non-profit Org.  
U.S. Postage  
PAID  
Dana-Farber



*Sarah Ferguson, the Duchess of York and global ambassador for Ronald McDonald House Charities, visits with Jimmy Fund Clinic patient Madeleine Savoie during a trip to Dana-Farber that she made in celebration of World Children's Day on Nov. 15.*

## MARCH / APRIL

### March

#### **24** The Second Annual Golf Ball

Dress to the "18s" for the Golf Ball, a golf-themed, black-tie gala to benefit brain tumor research from 6 p.m.–12:30 a.m. at the International Ballroom, Hilton Boston Logan Airport. Tickets are \$75 each and include gourmet dinner and appetizers. For more information, call 781-639-7010 or visit [www.par4cure.com](http://www.par4cure.com).



#### **30** Ovations for the Cure

Join Institute Trustee Patty Franchi Flaherty at the Westin Hotel in Waltham, Mass., for a luncheon and Stuart Weitzman fashion show to raise funds for the Madeline P. Franchi Ovarian Cancer Fund at DFCl. For more information, contact Lauren Nash at 617-632-3863.

### April

#### **7** Janet McDonald Memorial Walk Against Cancer

Join the friends and family of Janet McDonald for their 12th annual walk to support immunotherapy research at DFCl. The walk begins at 9 a.m. at Avon Baptist Church in Avon, Mass. For more information, contact Sarah Neukom at 617-632-5008 or visit [www.janetmcdonaldwalk.org](http://www.janetmcdonaldwalk.org).

#### **10** Rally Against Cancer<sup>SM</sup>

Show your team spirit for the Boston Red Sox and the Jimmy Fund as you wear your favorite Sox apparel to work on Opening Day at Fenway Park. Form a team at your place of work or school and raise the most money to win the grand prize: a visit from Red Sox player Kevin Youkilis! For more information, contact Charles Savicki at 617-632-5420 or visit [www.rallyagainstcancer.org](http://www.rallyagainstcancer.org).

#### **14-15** NASCAR Race Fest

Meet all your favorite speedway superstars at the Holyoke Mall at Ingleside in Holyoke, Mass. Several official teams and 80 NASCAR-certified vehicles will be on hand for two days of photo opportunities and fun at this inaugural event, sponsored by Gary Rome Hyundai. For more information, contact Janet Caparoso at 888-546-6938.

## APRIL / MAY

### April


#### **16** Dana-Farber Marathon Challenge

Join the race against cancer during the 111th running of the Boston Marathon® by supporting a runner or volunteering for the Dana-Farber Marathon Challenge. To make a gift or volunteer, call the Marathon hotline at 800-551-7036 or e-mail [dfmc@dfci.harvard.edu](mailto:dfmc@dfci.harvard.edu).



#### **27 & 28** Robert F. Campbell Jr. Memorial Hockey Tournament

Take the ice for this competitive hockey tournament featuring local ex-collegiate and junior hockey players from throughout New England—all playing to benefit leukemia research and patient care at DFCl. For more information, contact Liz and Jeff Campbell at 781-326-5603.



### May

#### **4** Friends of Dana-Farber Annual Gala

Join the Friends of Dana-Farber as they honor David and Eileen Perini at the Back Bay Events Center, 180 Berkeley Street, Boston. Tickets are \$350. For more information, contact the Friends office at 617-632-3021.

#### **7-13** Boston Bakes for Breast Cancer

Sweeten someone's day and help battle breast cancer by ordering a unique dessert prepared by one of more than 100 local chefs. All proceeds benefit the Eva Brownman Breast Cancer Fund, which supports Dana-Farber. For a list of participating restaurants, call Lauren Nash at 617-632-3863 or visit [www.bostonbakesforbreastcancer.org](http://www.bostonbakesforbreastcancer.org).



## JUNE

### June

#### **Jimmy Fund/Variety Children's Theatre Program**

Take part in the Jimmy Fund's most historic annual event by seeing a summer blockbuster at participating movie theatres and giving your spare change to help fight cancer. For more information or to volunteer, contact Sarah Curtis at 617-632-5091 or visit [www.jimmyfund.org/theatre](http://www.jimmyfund.org/theatre).

#### **3** Katelynn's Ride

Hop on your bike or support a rider in memory of Katelynn Battista. The seventh annual ride takes place at Hampshire College in Amherst, Mass., and offers a choice of four routes to its riders: from the challenging Century Ride to the kid-friendly, 10-mile ride. For more information, contact Kimberly Chisholm in the Jimmy Fund's Western New England office at 888-546-6938.

#### **3** Worcester Academy Jimmy Fund Walk and Rock

Lace up your sneakers for Worcester Academy's second annual 5K walk at Lake Park in Worcester, Mass. The afternoon trek will be followed by a fun family festival featuring food, games, and live rock music. For more information, visit [www.WalkandRock.com](http://www.WalkandRock.com) or contact Sarah Neukom at 617-632-5008.

#### **5-7** Jimmy Fund Scooper Bowl<sup>®</sup>

Taste the many delicious available flavors at the nation's largest all-you-can-eat ice cream festival. The 25th annual event will be held at City Hall Plaza, Boston, from 11:30 a.m. to 6 p.m. on Tuesday and Thursday, and from 11:30 a.m. to 8 p.m. on Wednesday. To purchase group tickets or for more information, contact Sarah Neukom at 617-632-5008 or visit [www.scooperbowl.org](http://www.scooperbowl.org).

#### **23** John Hancock Fantasy Day at Fenway

Fulfill your dream of playing baseball at legendary Fenway Park while helping strike out cancer. Contact Caitlin Fay at 617-632-4215 or visit [www.jimmyfund.org/fantasyday](http://www.jimmyfund.org/fantasyday) for ticket packages and up-to-date event information.